hTAB004 T-cell Engager / CAR-T
Pancreatic Cancer, Triple-Negative Breast Cancer
PreclinicalActive
Key Facts
Indication
Pancreatic Cancer, Triple-Negative Breast Cancer
Phase
Preclinical
Status
Active
Company
About OncoTAb
OncoTAb is a private, pre-revenue biotech company leveraging its patented tMUC1-targeting antibody platform to address unmet needs in oncology. Its initial focus is the commercial launch of the Agkura Personal Score, a blood-based diagnostic test for breast cancer detection in women with dense breasts, which represents a significant market opportunity. Beyond diagnostics, the company has a preclinical pipeline exploring the same targeting agent for therapeutic applications, including radioimmunotherapy and CAR-T cell therapies for breast and pancreatic cancers.
View full company profile